167 related articles for article (PubMed ID: 27214209)
1. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.
Petrelli F; Borgonovo K; Cabiddu M; Coinu A; Ghilardi M; Lonati V; Barni S
Br J Dermatol; 2016 Dec; 175(6):1166-1174. PubMed ID: 27214209
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
4. The extent to which the last decade has yielded additional treatment options for EGFR-associated rash besides classic treatment with antibiotics and corticosteroids - A systematic review.
Papoui E; Papastavrou E; Merkouris A; Charalambous A
Eur J Oncol Nurs; 2021 Feb; 50():101896. PubMed ID: 33493993
[TBL] [Abstract][Full Text] [Related]
5. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
8. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
Support Care Cancer; 2023 Dec; 32(1):8. PubMed ID: 38055053
[TBL] [Abstract][Full Text] [Related]
11. Impact of a pre-emptive skin treatment regimen on skin toxicities of anti-epidermal growth factor receptor monoclonal antibodies: more questions than answers.
Rother M
J Clin Oncol; 2010 Sep; 28(27):e474; author reply e475-6. PubMed ID: 20585089
[No Abstract] [Full Text] [Related]
12. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
Oskan F; Belka C; Manapov F
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
[No Abstract] [Full Text] [Related]
13. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
14. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
15. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2014 Dec; 26(6):359-68. PubMed ID: 24621163
[TBL] [Abstract][Full Text] [Related]
16. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
17. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
18. Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Nikolaou V; Strimpakos AS; Stratigos A; Katsambas A; Antoniou C; Syrigos KN
Dermatology; 2012; 224(4):315-9. PubMed ID: 22699716
[TBL] [Abstract][Full Text] [Related]
19. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
20. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
